Stockreport

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Fi...

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survival a [Read more]